NCT04445285View on ClinicalTrials.gov

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

November 30, 2021

Study Completion Date

February 28, 2022

Conditions
Covid19
Interventions
DRUG

Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)

2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses

DRUG

0.9%sodium chloride

Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses

Trial Locations (1)

36617

RECRUITING

University of South Alabama, Mobile

All Listed Sponsors
collaborator

University of South Alabama

OTHER

lead

Jon Simmons

OTHER